Samsung Electronics Co., Ltd.

Good T Cells, Inc.

Yonsei University

Hyundai Electronics Industries Co. Ltd.

Korea University Research and Business Foundation

Intron Biotechnology, Inc.

Samsung Sdi Co., Inc.

Mando Corporation

Kyungpook National University Industry-Academic Cooperation Foundation

Immunomet Therapeutics Inc.

Seoul Women's University Industry-University Cooperation Foundation

Global Agro.,ltd.

Beom Seok Kim

Jung Ho Kim

Ju Hyun Kim

Myungkwan Choi

Hyunseok Choi

Myung Sup Jung

Jong Hoon Won

Yong Joo Lee

Feifei Fang

Sangah Gam

Deuk Kyu Moon

Sang Ho Park

SAng Hyeon Kang

Seunghyun Lee

Seong Jun Yoon

Soo Youn Jun

Jee Soo Son

Bongjin Kuh

Hyung Hee Cho

Jin H Lee

Kyoung Bong Koo

Hoon Song

Jin Yong Kim

Dong Ho Lee

Wandon Kim

Ha Na Kim

Yong-Suk Tak

Myung-Sup Jung

Hanmei Choi

Jong Cheol Lee

Dong Yun Lee

Hyoun Rok Paik

Jae Jin Kim

Masashi Tsuji

Hyun-Seok Choi

Hye Young Kong

Boreum Jeong

Joungeun Yoo

Won Suk Chang

Kyuho Cho

Jong Jin Yoon

Myung Man Kim

Jun Su Park

Kyung Min Kim

Hyoung Rok Paik

Sunghyun Han

In Hwang Kim

Hyun Seok Choi

Hyun Jin Yu

Ohseong Kwon

Seung Hwan Song

Hong-Seok Lee

Woocheol Jeong

Seon Ho Kim

Ji Min Son

Tae-Rae Kim

Hyun Joo Im

Sung Dug Kim

Seong-Jun Yoon

Sunghwi Cho

Geun Woo Lee

Sang Jun Ha

Jongsung Lim

Hyuncheol Oh

Ki Hyun Ryu

Hwanseong Lee

Jung Kwuen An

Seung Mok Ryu

Jae Hong Choi

Woosung Ha

Ho Kyu Moon

Hokyu Moon

Geehong Choi

Jungsik Song

Donghwi Lee

Hoanju Yoo

Dong Il Shim

Bee-Gek Ng

Jae-Woo Han

Chui Hoon Kim

Chul Hoon Kim

Ki Chang Hong

Joung Woong Kim

Hyun Jong Cho

The present invention relates to abacteriophage STP-2 (Accession number: KCTC 12853BP) isolated from nature and characterized by having the ability to destroyand having a genome represented by SEQ ID NO:1; and to a method for preventing and treating diseases caused byusingbacteriophage STP-2 containing the same as an active ingredient.

bacteriophage STP-2 and use thereof for inhibiting proliferation of

The present invention relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is located on the surface of a regulatory T cell. The binding molecule provided in the present invention can activate the function of regulatory T cells to effectively prevent, ameliorate, or treat diseases caused by excessive activation or expression of various immune cells and inflammatory cells, for example, immune-related diseases such as autoimmune disease, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute or chronic inflammatory disease, etc. In addition, the binding molecule, preferably the antibody, specific for the Lrig-1 protein according to the present invention has advantages of more effectively targeting the Lrig-1 protein as compared with antibodies against Lrig-1 which are previously commercially available, and also possessing very good binding capacity thereto.

Binding molecule specific for Lrig-1 protein and use thereof

The present invention relates to a cancer-specific tumor antigen neoepitope represented by any one of SEQ ID NOs: 1 to 214, an antigen-presenting cell loaded with the neoepitope, and a method for activating T cells for cancer treatment using the antigen-presenting cell. An antigen-presenting cell, that is, a dendritic cell, loaded with a cancer-specific tumor antigen epitope provided in the present invention enables rapid and effective induction of differentiation and proliferation of cancer antigen-specific T cells, preferably memory T cells, and the memory T cells thus activated can treat a cancerous or neoplastic condition or prevent recurrence, progression, or metastasis of cancer while avoiding the defense mechanism of cancer cells.

Method for activating T cells for cancer treatment

The present invention relates to a cancer-specific tumor antigen neoepitope represented by any one of SEQ ID NOs: 1 to 184, an antigen-presenting cell loaded with the neoepitope, and a method for activating T cells for cancer treatment using the antigen-presenting cell. An antigen-presenting cell, that is, a dendritic cell, loaded with a cancer-specific tumor antigen epitope provided in the present invention enables rapid and effective induction of differentiation and proliferation of cancer antigen-specific T cells, preferably memory T cells, and the memory T cells thus activated can treat a cancerous or neoplastic condition or prevent recurrence, progression, or metastasis of cancer while avoiding the defense mechanism of cancer cells.

The present invention relates to a composition for prevention or treatment of hair loss. The composition is effectively delivered into hair papilla cells in a hair loss area, which is a target area, wherein a cytokine or enzyme highly expressed in the hair loss area causes a drug to be separated from a compound contained in the composition so that the drug effectively exhibits activity, which ultimately promotes hair growth and/or hair regrowth.

Composition for prevention or treatment of hair loss

Provided are a pharmaceutical composition for preventing or treating inflammatory disease, autoimmune disease, graft rejection responses, or combinations thereof, the pharmaceutical composition including a compound represented by Formula 1, or a stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof, and a method using the pharmaceutical composition. The pharmaceutical composition and the method can be used to effectively prevent or treat inflammatory disease, autoimmune disease, graft rejection responses, or combinations thereof.

Pharmaceutical compositions for preventing or treating inflammatory disease, autoimmune disease, or combination thereof, and method for using same

The present invention relates to a fusion protein comprising an extracellular domain of leucine-rich and immunoglobulin-like domains-1 (Lrig-1) protein and an immunoglobulin Fc region. The fusion protein provided in the present invention can interact with a ligand for Lrig-1 protein, which is present on effector T cells, to inhibit the interaction between the effector T cells and regulatory T cells (Treg cells) having the Lrig-1 protein on their surface, so that activity of the regulatory T cells is inhibited and activity of the effector T cells is maintained or elevated, thereby effectively inhibiting growth of cancer cells, in particular, solid cancer cells.

Fusion protein, and pharmaceutical composition for preventing or treating cancer, containing same

A composition for preventing or treating an infection or disease caused by a pathogenicincludes a Podoviridae bacteriophage (Esc-COP-30) having an ability to lyse the pathogenicand a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenicincludes administering to a subject a Podoviridae bacteriophage and lysing the pathogenicby the Podoviridae bacteriophage.

Compositions and methods for inhibiting the proliferation of pathogenic

The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.

Pharmaceutical composition for preventing or treating adverse drug reactions by statin

The present invention relates to a composition for preventing or treating chronic allograft dysfunction, comprising bisphosphonate which is used as a therapeutic agent for osteoporosis. The composition for preventing or treating chronic allograft dysfunction, comprising bisphosphonate, according to the present invention has an excellent prophylactic and/or therapeutic effect on chronic allograft dysfunction caused by a gradual decrease in the function of a transplanted tissue or organ which occurs after tissue or organ transplantation surgery, and thus is expected to be able to remarkably increase a long-term survival after transplantation surgery.

Composition for treating chronic renal transplant dysfunction comprising bisphosphonate

The present invention relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is on the surface of regulatory T cells. The binding molecule provided in the present invention can suppress the function of regulatory T cells to effectively prevent, ameliorate, or treat cancer, particularly solid tumor. The binding molecule has advantages of more effectively targeting the Lrig-1 protein as compared with antibodies against Lrig-1 which are previously commercially available, and also possessing very good binding capacity thereto.

The present disclosure relates to a novel recombinant BAF57 fusion protein and the use thereof as a composition capable of effectively preventing or treating inflammatory disease, immune-related disease or cancer. The fusion protein provided in the present disclosure may be delivered into cells, bind to BAF155 or other BAF complex subunit, and act as a competitive inhibitor of BAF57 present in the cell, thereby lowering the expression level of BAF57 by a protein degradation mechanism, thereby effectively preventing, ameliorating or treating various diseases such as inflammatory disease, immune-related disease or cancer.

Recombinant fusion protein of BAF57 and uses thereof

Binding molecule specific for LRIG-1 protein and use thereof

A diffractive optical element including a diffraction layer including a plurality of optical axes along an in-plane direction, wherein the diffraction layer includes an anisotropic material that satisfies one of Relationship Equations 1A to 3A&#x394;(450 nm)&#x3c;&#x394;(550 nm)&#x2264;&#x394;(650 nm)&#x2003;&#x2003;Relationship Equation 1A&#x394;(450 nm)&#x2264;&#x394;(550 nm)&#x3c;&#x394;(650 nm)&#x2003;&#x2003;Relationship Equation 2A&#x394;(450 nm)=&#x394;(550 nm)=&#x394;(650 nm)&#x2003;&#x2003;Relationship Equation 3Awherein, in Relationship Equations 1A to 3A,

Diffractive optical element and device

A method for controlling plant viruses comprising treating plant or soil with a composition for controlling plant viruses comprising Trichodermin wherein the composition has antiviral activity against plant viruses when applied to a plant or to soil. In some embodiments, the Trichodermin is isolated from astrain.

Method for controlling plant viruses using antiviral composition comprising trichodermin

Growing community of inventors

Seoul, South Korea

Beom Seok Kim